Opendata, web and dolomites

WITHDRAWAL AFTERMATH

The Aftermath of a Drug Withdrawal: Modeling Spillover Effects Across Countries and Across Categories

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "WITHDRAWAL AFTERMATH" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITEIT ROTTERDAM 

Organization address
address: BURGEMEESTER OUDLAAN 50
city: ROTTERDAM
postcode: 3062 PA
website: www.eur.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.eur.nl
 Total cost 177˙598 €
 EC max contribution 177˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITEIT ROTTERDAM NL (ROTTERDAM) coordinator 177˙598.00

Map

 Project objective

The pharmaceutical market is one of the most important industries in the global economy. Projections are that spending on medicines will grow to 1.2 trillion US$ in 2016. Marketing has an important impact in this pharmaceutical industry, but has a particularly negative image. The growing pharmaceutical market increases the pressure for the regulators to approve new medicines and for firms the pressure to market their drugs to stay ahead of the competition. These forces have contributed to the fact that over the past decade many drugs were approved too early, and the number of withdrawn drugs has doubled. A drug withdrawal is when a drug is taken off the market, because it is considered to be harmful typically due to unexpected adverse effects (including deaths). Since the pharmaceutical market directly concerns population health, drug withdrawals can have disastrous consequences. While there has been some research done into the aftermath of a withdrawal from the perspective of the focal drug, very little research has been done on the spillover effects. This project is the first to explicitly focus on spillover effects in the aftermath of drug withdrawals. There are two types of spillover effects to consider (i) across drugs (Do doctors start prescribing the competing drug, or has the withdrawal a negative spillover effect?), and (ii) across countries (If a country lags in withdrawing a drug, does the withdrawal in leading countries spill over?). Advanced econometric techniques will be used to model the dynamics before and after withdrawals, including spillover effects and the dynamics between sales and marketing. Results of this project will not only benefit managers of pharmaceutical firms, but is also important from an economic (i.e. given the size of pharmaceutical market) and societal (i.e. the high profile nature of withdrawals and the role of government agencies) perspective.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WITHDRAWAL AFTERMATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WITHDRAWAL AFTERMATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ProTeCT (2019)

Proteasome as a target to combat trichomoniasis

Read More  

PRISME (2019)

PRogram for ISolation Manufacturing in Europe (PRISME)

Read More  

ASIQS (2019)

Antiferromagnetic spintronics investigated by quantum sensing techniques

Read More